Clinical Trials Logo

Scleroderma, Limited clinical trials

View clinical trials related to Scleroderma, Limited.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04927390 Active, not recruiting - Systemic Sclerosis Clinical Trials

Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

MINIMISE
Start date: December 8, 2021
Phase: Phase 2
Study type: Interventional

Systemic sclerosis or scleroderma is an autoimmune condition that cause thickening and hardening of the skin, but can also affect internal organs. There are two major subsets of scleroderma: the limited cutaneous systemic sclerosis (lcSSc) that usually affects the skin of the face, neck, lower legs or lower arms, but can also lead to internal organ complications, and the diffuse cutaneous systemic sclerosis (dcSSc) that may affect blood circulation and internal organs, as well as the skin. To date there is no drug that has been definitively proven to cure or modify the course of scleroderma. However, there is emerging evidence that immunosuppression and specifically mycophenolate mofetil (MMF) may be beneficial in lcSSc. The MINIMISE-Pilot trial would be an important first step to evaluate the risk and potential benefit to this disease group. MMF as the intervention of choice is both appropriate and timely, as it has been routinely used in the management of dcSSc. The aim of this pilot trial is to explore whether the immunosuppressive agent MMF can slow down disease progression in patients with lcSSc compared to the current standard of care alone. This pilot trial will also provide critical information for the development of a future large trial that could potentially transform lcSSc patient management.